Krishaa Biotech Profile
Key Indicators
- Authorised Capital ₹ 2.00 Cr
as on 06-07-2024
- Paid Up Capital ₹ 2.00 Cr
as on 06-07-2024
- Company Age 9 Year, 6 Months
- Last Filing with ROC 31 Mar 2018
- Open Charges ₹ 1.00 Cr
as on 06-07-2024
- Revenue 24.36%
(FY 2018)
- Profit 996.68%
(FY 2018)
- Ebitda 13113.68%
(FY 2018)
- Net Worth 1471.36%
(FY 2018)
- Total Assets -65.04%
(FY 2018)
About Krishaa Biotech
The Corporate was formerly known as Maxgrow Cement Private Limited. The Company is engaged in the Chemicals And Materials Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2018. It's a company limited by shares with an authorized capital of Rs 2.00 Cr and a paid-up capital of Rs 2.00 Cr.
The company currently has active open charges totaling ₹1.00 Cr.
Manoj Thakar and Ashokkumar Dansingani serve as directors at the Company.
- CIN/LLPIN
U24100WB2015PTC206682
- Company No.
206682
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
11 Jun 2015
- Date of AGM
20 Sep 2018
- Date of Balance Sheet
31 Mar 2018
- Listing Status
Unlisted
- ROC Code
Roc Kolkata
Industry
Company Details
- Location
Kolkata, West Bengal, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Krishaa Biotech?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Manoj Thakar  | Additional Director | 01-Mar-2019 | Current |
| Ashokkumar Dansingani | Additional Director | 01-Mar-2019 | Current |
Financial Performance and Corporate Structure Insights of Krishaa Biotech.
Krishaa Biotech Private Limited, for the financial year ended 2018, experienced significant growth in revenue, with a 24.36% increase. The company also saw a substantial improvement in profitability, with a 996.68% increase in profit. The company's net worth Soared by an impressive increase of 1471.36%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Krishaa Biotech?
In 2018, Krishaa Biotech had a promoter holding of 0.01% and a public holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Millinique Trades LlpActive 5 years 7 monthsManoj Thakar and Ashokkumar Dansingani are mutual person
- Mendeleev Trades LimitedActive 16 years 10 months
Manoj Thakar and Ashokkumar Dansingani are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Others Creation Date: 25 Jul 2016 | ₹1.00 Cr | Open |
How Many Employees Work at Krishaa Biotech?
Unlock and access historical data on people associated with Krishaa Biotech, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Krishaa Biotech, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Krishaa Biotech's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
